[144] BioNTech SE American Depositary Share SEC Filing
Form 144 filing for BioNTech SE (BNTX) shows a proposed sale of 1,774,837 American Depositary Shares representing ordinary shares, with an aggregate market value of $200,024,129.90. The sale is reported through Berenberg Capital Markets LLC on 08/15/2025 and the shares are listed on the Nasdaq Global Select. The filing discloses that the seller acquired the underlying ordinary shares via stock option exercises on 08/09/2024 (918,651 shares) and 11/21/2022 (856,186 shares). The filing reports no sales in the prior three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Dichiarazione Form 144 per BioNTech SE (BNTX) indica una proposta di vendita di 1.774.837 American Depositary Shares rappresentative di azioni ordinarie, per un valore di mercato complessivo di $200.024.129,90. La vendita 猫 segnalata tramite Berenberg Capital Markets LLC in data 15/08/2025 e le azioni sono quotate al Nasdaq Global Select. La comunicazione specifica che il venditore ha acquisito le azioni ordinarie sottostanti mediante esercizio di opzioni su azioni il 09/08/2024 (918.651 azioni) e il 21/11/2022 (856.186 azioni). Il modulo non riporta vendite nei tre mesi precedenti e contiene la consueta dichiarazione secondo cui il venditore non 猫 a conoscenza di informazioni materiali sfavorevoli non divulgate.
Formulario 144 para BioNTech SE (BNTX) muestra una propuesta de venta de 1.774.837 American Depositary Shares que representan acciones ordinarias, con un valor de mercado agregado de $200.024.129,90. La venta se informa a trav茅s de Berenberg Capital Markets LLC el 15/08/2025 y las acciones cotizan en el Nasdaq Global Select. La presentaci贸n revela que el vendedor adquiri贸 las acciones ordinarias subyacentes mediante ejercicios de opciones sobre acciones el 09/08/2024 (918.651 acciones) y el 21/11/2022 (856.186 acciones). La declaraci贸n no reporta ventas en los tres meses previos e incluye la representaci贸n habitual de que el vendedor no tiene conocimiento de informaci贸n material adversa no divulgada.
BioNTech SE (BNTX) 鞝滌稖 Form 144鞚� 氤错喌欤茧ゼ 雮橅儉雮措姅 1,774,837欤�(氙戈淡鞓堩儊欤检嫕)鞚� 毵り皝 鞝滌晥鞚� 氤挫棳欤茧┌, 齑� 鞁滉皜 臧�鞎§潃 $200,024,129.90鞛呺媹雼�. 頃措嫻 毵り皝鞚� 2025-08-15鞐� Berenberg Capital Markets LLC毳� 韱淀暣 氤搓碃霅橃棃瓿�, 欤检嫕鞚� Nasdaq Global Select鞐� 靸侅灔霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滌棎電� 毵る弰鞚胳澊 旮办磮 氤错喌欤茧ゼ 欤检嫕 鞓奠厴 頄夓偓搿� 旆摑頃� 雮犾臧� 2024-08-09(918,651欤�)鞕赌 2022-11-21(856,186欤�)搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 斓滉芳 3臧滌洈 雮� 毵る弰 旮半鞚� 鞐嗢溂氅�, 鞝滌稖靹滌棎電� 毵る弰鞚胳澊 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞚胳頃橁碃 鞛堨 鞎婋嫟電� 響滌鞝� 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
D茅claration Form 144 pour BioNTech SE (BNTX) indique une proposition de vente de 1 774 837 American Depositary Shares repr茅sentant des actions ordinaires, pour une valeur marchande totale de 200 024 129,90 $. La vente est signal茅e via Berenberg Capital Markets LLC le 15/08/2025 et les actions sont cot茅es sur le Nasdaq Global Select. Le d茅p么t r茅v猫le que le vendeur a acquis les actions ordinaires sous-jacentes par exercice d鈥檕ptions sur actions le 09/08/2024 (918 651 actions) et le 21/11/2022 (856 186 actions). Le document ne rapporte aucune vente au cours des trois mois pr茅c茅dents et comporte la d茅claration standard selon laquelle le vendeur n鈥檃 pas connaissance d鈥檌nformations d茅favorables importantes non divulgu茅es.
Formular 144 f眉r BioNTech SE (BNTX) weist einen vorgeschlagenen Verkauf von 1.774.837 American Depositary Shares dar, die Stammaktien repr盲sentieren, mit einem aggregierten Marktwert von $200.024.129,90. Der Verkauf wird 眉ber Berenberg Capital Markets LLC am 15.08.2025 gemeldet und die Aktien sind am Nasdaq Global Select notiert. Die Einreichung gibt an, dass der Verk盲ufer die zugrunde liegenden Stammaktien durch Aus眉bung von Aktienoptionen am 09.08.2024 (918.651 Aktien) und am 21.11.2022 (856.186 Aktien) erworben hat. In den vorangegangenen drei Monaten werden keine Verk盲ufe berichtet, und es ist die 眉bliche Erkl盲rung enthalten, dass dem Verk盲ufer keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.
- Clear provenance of shares: The filing specifies the shares were acquired via stock option exercises on 11/21/2022 and 08/09/2024, providing transparency on origin.
- Broker identified: Berenberg Capital Markets LLC is named, giving a clear execution channel for the proposed sale.
- Large block size: The proposed sale totals 1,774,837 ADSs with aggregate market value of $200,024,129.90, which could increase share supply on the sale date.
- Potential near-term selling pressure: The specified approximate sale date is 08/15/2025, concentrating supply on a single day (as reported).
Insights
TL;DR: A planned sale of 1.77M ADSs valued at ~$200M is reported; timing and size are material to share supply but not a change in issuer operations.
The filing documents a single proposed transaction executed through a broker on 08/15/2025 for 1,774,837 ADSs with an aggregate market value of $200,024,129.90. The underlying shares were obtained by stock option exercises in 2022 and 2024, indicating these are insider/beneficiary-originated shares rather than newly issued stock. No sales in the prior three months are reported, and the seller provides the standard representation regarding material nonpublic information. From a market-impact perspective, the block size is explicit; assessing pricing pressure requires market depth data not present in the filing.
TL;DR: The notice is a routine required disclosure of a proposed sale under Rule 144, documenting source and broker details.
The form lists Berenberg Capital Markets LLC as the broker and records acquisition details (stock option exercises on 11/21/2022 and 08/09/2024) for a total of 1,774,837 ADSs to be sold. The filing includes the attestations required by the form, including the statement that the seller is unaware of undisclosed material adverse information. There are no governance events, legal disclaimers beyond standard warnings, or other corporate actions disclosed in this submission.
Dichiarazione Form 144 per BioNTech SE (BNTX) indica una proposta di vendita di 1.774.837 American Depositary Shares rappresentative di azioni ordinarie, per un valore di mercato complessivo di $200.024.129,90. La vendita 猫 segnalata tramite Berenberg Capital Markets LLC in data 15/08/2025 e le azioni sono quotate al Nasdaq Global Select. La comunicazione specifica che il venditore ha acquisito le azioni ordinarie sottostanti mediante esercizio di opzioni su azioni il 09/08/2024 (918.651 azioni) e il 21/11/2022 (856.186 azioni). Il modulo non riporta vendite nei tre mesi precedenti e contiene la consueta dichiarazione secondo cui il venditore non 猫 a conoscenza di informazioni materiali sfavorevoli non divulgate.
Formulario 144 para BioNTech SE (BNTX) muestra una propuesta de venta de 1.774.837 American Depositary Shares que representan acciones ordinarias, con un valor de mercado agregado de $200.024.129,90. La venta se informa a trav茅s de Berenberg Capital Markets LLC el 15/08/2025 y las acciones cotizan en el Nasdaq Global Select. La presentaci贸n revela que el vendedor adquiri贸 las acciones ordinarias subyacentes mediante ejercicios de opciones sobre acciones el 09/08/2024 (918.651 acciones) y el 21/11/2022 (856.186 acciones). La declaraci贸n no reporta ventas en los tres meses previos e incluye la representaci贸n habitual de que el vendedor no tiene conocimiento de informaci贸n material adversa no divulgada.
BioNTech SE (BNTX) 鞝滌稖 Form 144鞚� 氤错喌欤茧ゼ 雮橅儉雮措姅 1,774,837欤�(氙戈淡鞓堩儊欤检嫕)鞚� 毵り皝 鞝滌晥鞚� 氤挫棳欤茧┌, 齑� 鞁滉皜 臧�鞎§潃 $200,024,129.90鞛呺媹雼�. 頃措嫻 毵り皝鞚� 2025-08-15鞐� Berenberg Capital Markets LLC毳� 韱淀暣 氤搓碃霅橃棃瓿�, 欤检嫕鞚� Nasdaq Global Select鞐� 靸侅灔霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滌棎電� 毵る弰鞚胳澊 旮办磮 氤错喌欤茧ゼ 欤检嫕 鞓奠厴 頄夓偓搿� 旆摑頃� 雮犾臧� 2024-08-09(918,651欤�)鞕赌 2022-11-21(856,186欤�)搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 斓滉芳 3臧滌洈 雮� 毵る弰 旮半鞚� 鞐嗢溂氅�, 鞝滌稖靹滌棎電� 毵る弰鞚胳澊 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞚胳頃橁碃 鞛堨 鞎婋嫟電� 響滌鞝� 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
D茅claration Form 144 pour BioNTech SE (BNTX) indique une proposition de vente de 1 774 837 American Depositary Shares repr茅sentant des actions ordinaires, pour une valeur marchande totale de 200 024 129,90 $. La vente est signal茅e via Berenberg Capital Markets LLC le 15/08/2025 et les actions sont cot茅es sur le Nasdaq Global Select. Le d茅p么t r茅v猫le que le vendeur a acquis les actions ordinaires sous-jacentes par exercice d鈥檕ptions sur actions le 09/08/2024 (918 651 actions) et le 21/11/2022 (856 186 actions). Le document ne rapporte aucune vente au cours des trois mois pr茅c茅dents et comporte la d茅claration standard selon laquelle le vendeur n鈥檃 pas connaissance d鈥檌nformations d茅favorables importantes non divulgu茅es.
Formular 144 f眉r BioNTech SE (BNTX) weist einen vorgeschlagenen Verkauf von 1.774.837 American Depositary Shares dar, die Stammaktien repr盲sentieren, mit einem aggregierten Marktwert von $200.024.129,90. Der Verkauf wird 眉ber Berenberg Capital Markets LLC am 15.08.2025 gemeldet und die Aktien sind am Nasdaq Global Select notiert. Die Einreichung gibt an, dass der Verk盲ufer die zugrunde liegenden Stammaktien durch Aus眉bung von Aktienoptionen am 09.08.2024 (918.651 Aktien) und am 21.11.2022 (856.186 Aktien) erworben hat. In den vorangegangenen drei Monaten werden keine Verk盲ufe berichtet, und es ist die 眉bliche Erkl盲rung enthalten, dass dem Verk盲ufer keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.
FAQ
What does the Form 144 filed for BioNTech (BNTX) disclose?
How were the shares being sold by the filer acquired?
Does the filing report any sales in the prior three months for the seller?
Which exchange will the ADSs be sold on?
Who is the broker handling the proposed sale?
